Research programme: cancer immunotherapies - Sellas Life Sciences/Advaxis

Drug Profile

Research programme: cancer immunotherapies - Sellas Life Sciences/Advaxis

Alternative Names: ADXS; WT1-Lm Product - Sellas Life Scieces

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advaxis; Sellas Life Sciences Group
  • Class Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Feb 2018 Preclinical trials in Cancer in USA (Parenteral) (Sellas Life Sciences, February 2018)
  • 26 Feb 2018 Sellas Life Sciences plans a phase I trial for Cancer in the first half of 2018 (Sellas Life Sciences pipeline, February 2018)
  • 27 Feb 2017 Advaxis and SELLAS Life Sciences intend to file an IND application for Lm-based antigen delivery of galinpepimut-S in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top